Literature DB >> 19549580

Infections in patients with multiple myeloma.

Marcio Nucci1, Elias Anaissie.   

Abstract

Infectious diseases are the leading causes of death in patients with multiple myeloma (MM). Major changes have occurred in the spectrum of infections paralleling the changes in the treatment of MM. Bacteria (particularly gram-negative organisms) are the most frequent etiologic agents, and invasive fungal infections caused by molds (Aspergillus sp. and Fusarium sp.) have been increasingly reported. New infections have emerged with an increase in the intensity of the treatment of MM. Management of infections in MM patients must include recognition of the likely pathogens. Specific strategies of diagnosis, prophylaxis, and empirical and specific therapy are based on host factors and probable pathogens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549580     DOI: 10.1053/j.seminhematol.2009.03.006

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  14 in total

Review 1.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

Review 2.  State of the art diagnostic of mold diseases: a practical guide for clinicians.

Authors:  F Beirão; R Araujo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-18       Impact factor: 3.267

3.  European Myeloma Network guidelines for the management of multiple myeloma-related complications.

Authors:  Evangelos Terpos; Martina Kleber; Monika Engelhardt; Sonja Zweegman; Francesca Gay; Efstathios Kastritis; Niels W C J van de Donk; Benedetto Bruno; Orhan Sezer; Annemiek Broijl; Sara Bringhen; Meral Beksac; Alessandra Larocca; Roman Hajek; Pellegrino Musto; Hans Erik Johnsen; Fortunato Morabito; Heinz Ludwig; Michele Cavo; Hermann Einsele; Pieter Sonneveld; Meletios A Dimopoulos; Antonio Palumbo
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

4.  Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma.

Authors:  Srirama Josyula; Margot J Pont; Sayan Dasgupta; Xiaoling Song; Sushma Thomas; Gregory Pepper; Jacob Keane-Candib; Terry L Stevens-Ayers; Hans D Ochs; Michael J Boeckh; Stanley R Riddell; Andrew J Cowan; Elizabeth M Krantz; Damian J Green; Joshua A Hill
Journal:  Transplant Cell Ther       Date:  2022-03-11

5.  Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors.

Authors:  Toni Valković; Vedrana Gačić; Jelena Ivandić; Božo Petrov; Renata Dobrila-Dintinjana; Elizabeta Dadić-Hero; Antica Načinović-Duletić
Journal:  Turk J Haematol       Date:  2015-09       Impact factor: 1.831

6.  Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib therapy.

Authors:  Juan Li; Ying Li; Beihui Huang; Dong Zheng; Mei Chen; Zhenhai Zhou
Journal:  Cell Biochem Biophys       Date:  2015-01       Impact factor: 2.194

7.  Patients With Multiple Myeloma Have More Complications After Surgical Treatment of Hip Fracture.

Authors:  Kwan Jun Park; Mariano E Menendez; Simon C Mears; C Lowry Barnes
Journal:  Geriatr Orthop Surg Rehabil       Date:  2016-07-14

Review 8.  How I treat elderly patients with plasma cell dyscrasias.

Authors:  Maria Gavriatopoulou; Despoina Fotiou; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Evangelos Terpos; Meletios Athanasios Dimopoulos
Journal:  Aging (Albany NY)       Date:  2018-12-18       Impact factor: 5.682

Review 9.  Treatment-related symptom management in patients with multiple myeloma: a review.

Authors:  Kathleen Colson
Journal:  Support Care Cancer       Date:  2015-02-03       Impact factor: 3.359

10.  Multiple Myeloma Index for Risk of Infection.

Authors:  Valkovic T; Gacic V; Nacinovic-Duletic A
Journal:  J Cancer       Date:  2018-06-04       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.